Louis VanderMolen, MD

Professor of Clinical Medicine

Vice Chair of Clinical Oncology, Orange County Program

Image of Louis VanderMolen, MD
Is this your profile? Click to edit

Overview

Dr. VanderMolen earned his medical degree from Loyola University Stritch School of Medicine. He performed his Internal Medicine Internship and Residency from Baylor College of Medicine- Texas Medical Center. He then went on to complete two fellowships, the first in hematology at Baylor, and the second in oncology at National Cancer Institute- Clinical Oncology Program.

Awards

  • Phi Beta Kappa: Elected Member, 1977
  • Baylor College of Medicine: Chief Resident, Internal Medicine, 1983
     – 1984
  • Orange County Medical Association: Physician of Excellence Award, 2006
     – 2013

Publications

  • ER-Targeted PET for Initial Staging and Suspected Recurrence in ER-Positive Breast Cancer. JAMA Netw Open. 2024 07 01; 7(7):e2423435.. View in PubMed
  • Dotatate PET/CT and 225Ac-Dotatate Therapy for Somatostatin Receptor-expressing Metastatic Breast Cancer. Radiology. 2024 07; 312(1):e233408.. View in PubMed
  • Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic melanoma? Cancer Biother Radiopharm. 2012 Aug; 27(6):337-43. Dillman RO, Barth NM, VanderMolen LA , Mahdavi . View in PubMed
  • Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic renal cell cancer? Cancer Biother Radiopharm. 2011 Jun; 26(3):273-7. Dillman RO, Barth NM, VanderMolen LA , . View in PubMed
  • A retrospective study of induction chemotherapy with docetaxel, cisplatinum, and 5-fluorouracil followed by concurrent radiotherapy with cetuximab in locally advanced head and neck cancer. Am J Otolaryngol. 2012 Jan-Feb; 33(1):93-7.. View in PubMed
  • High-dose chemotherapy and autologous stem cell rescue for metastatic breast cancer: superior survival for tandem compared with single transplants. Am J Clin Oncol. 2005 Jun; 28(3):281-8.. View in PubMed
  • Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinoma. Cancer Biother Radiopharm. 2004 Oct; 19(5):570-80.. View in PubMed
  • Does continuous-infusion interleukin-2 increase survival in metastatic melanoma? Am J Clin Oncol. 2003 Apr; 26(2):141-5. Dillman RO, O’Connor AA, Simpson L, Barth NM, VanderMolen LA , Vanderplas P . View in PubMed
  • Successful treatment of transitional cell carcinoma of the urethra with chemotherapy. Cancer Invest. 2002; 20(2):206-7.. View in PubMed
  • Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma. Cancer Biother Radiopharm. 2001 Feb; 16(1):47-54.. View in PubMed